Needham & Company LLC reaffirmed their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. Needham & Company LLC currently has a $76.00 target price on the stock. MLTX has been the subject of several other reports. Bryan, Garnier & Co […]
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising.
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking.
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price […]